The unaffordable cost of M&A-driven drug prices
Goozner, M.
Modern Healthcare 46(35): 24
2016
ISSN/ISBN: 0160-7480 PMID: 30452799 Document Number: 685836
Last week, Pfizer announced the $14 billion acquisition of Medivation, whose innovative prostate cancer treatment Xtandi (generic name enzalutamide) generated $2.2 billion in sales last year. The drug retails for $129,00 a year.
Document emailed within 1 workday
Related Documents
Tran, B.X.; Ohinmaa, A.; Duong, A.T.; Nguyen, L.T.; Vu, P.X.; Mills, S.; Houston, S.; Jacobs, P. 2012: Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics Drug and Alcohol Dependence 125(3): 260-266Terris-Prestholt, F.; Foss, A.M.; Cox, A.P.; Heise, L.; Meyer-Rath, G.; Delany-Moretlwe, S.; Mertenskoetter, T.; Rees, H.; Vickerman, P.; Watts, C.H. 2014: Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices Bmc Infectious Diseases 14: 14
Rutten, F.F. 1996: Pharmaco-economics and drug prices Nederlands Tijdschrift Voor Geneeskunde 140(45): 2216-2219
Kelley, T. 2017: Drug Prices: Why So High and Why So #&*! Complicated Managed Care 26(12): 14-16
Tallon, R. 1995: Cost-effective wound care: new priorities driven by outcomes Advances in Wound Care: the Journal for Prevention and Healing 8(5): 48
Lubell, J. 2010: Out is in; in is out. Reform law lowers drug prices--for outpatient only Modern Healthcare 40(18): 12-13
Huff, B. 2002: Patient care squeezed by soaring drug prices Gmhc Treatment Issues: the Gay Men's Health Crisis Newsletter of Experimental Aids Therapies 16(4): 1-7
Weissenstein, E. 1992: Senate proposal would reduce drug prices for federal agencies Modern Healthcare 22(33): 20
Castellucci, M. 2016: Taking the initiative in healthcare: will California voters cap drug prices? Modern Healthcare 46(43): 8; 10
Fong, T. 2004: Rules and regulations. CMS addresses drug prices, payment rates Modern Healthcare 34(31): 8-9 13
Greene, J. 2018: Why drug prices will continue to roil the waters-and why Scott Gottlieb, MD, will be in the center of the action Managed Care 27(12): 23-28
Herman, B. 2015: ACA coverage expansion at risk...battle against high drug prices...growing government business Modern Healthcare 45(1): 20
Crawford, W.A. 1971: Accident proneness: an unaffordable philosophy Medical Journal of Australia 2(18): 905-909
Bermúdez-Aza, E.H.; Kerr, L.R.F.S.; Kendall, C.; Pinho, A.A.; de Mello, M.B.; Mota, R.S.; Guimarães, M.D.C.; Alencar, C.S.; de Brito, A.M.; Dourado, I.C.; da Batista, S.M.B.; Abreu, F.; de Oliveira, L.C.; de Souza Moraes, A.ão.; Benzaken, A.S.; Merchan-Hamann, E.; de Freitas, G.M.B.ão.; McFarland, W.; Albuquerque, E.; Rutherford, G.W.; Sabino, E. 2011: Antiretroviral drug resistance in a respondent-driven sample of HIV-infected men who have sex with men in Brazil Journal of Acquired Immune Deficiency Syndromes 57(Suppl 3): S186-S192
DeKruyff, R.H.; Gieni, R.S.; Umetsu, D.T. 1997: Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40 Journal of Immunology 158(1): 359-366
Scrutton, M.C. 1993: The platelet as a Ca(2+)-driven cell: mechanisms which may modulate Ca(2+)-driven responses Advances in Experimental Medicine and Biology 344: 1-15
Gulland, A. 2015: Child immunisation is becoming unaffordable in some countries, charity warns Bmj 350: H303
Bush, K.; Mobashery, S. 1998: How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention Advances in Experimental Medicine and Biology 456: 71-98
Pearce, M.J.; Begg, E.J. 1994: Hospital drug therapy cost containment through a preferred medicines list and drug utilisation review system New Zealand Medical Journal 107(974): 101-104
Malekinejad, M.; Mohraz, M.; Razani, N.; Akbari, G.; McFarland, W.; Khairandish, P.; Malekafzali, H.; Gouya, M.M.; Zarghami, A.; Rutherford, G.W. 2015: High HIV prevalence in a respondent-driven sampling survey of injection drug users in Tehran, Iran Aids and Behavior 19(3): 440-449